Baseline erythropoietin level predicts Luspatercept response in Chinese patients with myelodysplastic syndrome: a propensity score-matched analysis
This first matched real-world study of luspatercept in Chinese MDS patients confirms its efficacy in reducing transfusion needs and identifies baseline erythropoietin level as a clinically meaningful predictor of response. These findings support the integration of EPO-guided selection in personalized treatment strategies.
Authors
- Xialin Zhang (ORCID: https://orcid.org/0000-0002-2234-3106)
- Meiling Zhao (ORCID: https://orcid.org/0000-0002-5422-2173)
- Doudou Chang (ORCID: https://orcid.org/0009-0008-3937-8365)
- Jia Wei (ORCID: https://orcid.org/0000-0002-0518-6970)
- Ruijuan Zhang (ORCID: https://orcid.org/0000-0003-1147-9240)
- Junyan Zhang (ORCID: https://orcid.org/0000-0002-7890-3707)
Institutions
- Shanxi Medical University (CN)
- First Hospital of Shanxi Medical University (CN)
- Shanxi Academy of Medical Sciences (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Leukemia Research Reports
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.lrr.2025.100532
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00